Clinical Trial Update: cfDNA Methylation for Liver Cancer Recurrence Detection

View source ↗

Summary

A prospective clinical trial is recruiting to evaluate cfDNA methylation as a biomarker for detecting recurrence in primary liver cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Wuhan Ammunition Life-tech Co., Ltd | Conditions: Primary Liver Cancer | Status: RECRUITING